2025 中期報告 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 管理層討論與分析 | | 29 | 企業管治及其他資料 | | 50 | 簡明綜合財務報表審閱報告 | | 52 | 簡 明綜合損益及其他全面收益表 | | 54 | 簡 明綜合財務狀況表 | | 56 | 簡 明綜合權益變動表 | | 58 | 簡 明綜合現金流量表 | | 61 | 簡 明綜合財務 報 表 附 註 | | 89 | 釋 義 | | 公司資料 | | --- | （截至二零二五年六月三十日） | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech (Hangzhou) Inc. | | 法定代表： | 林浩昇先生 | | 董事長： | 胡定旭先生 | | 註冊資本： | 人民幣441,011,443元 | | 中國總部： | | | 註冊及辦事處地址： | 中國杭州濱江區江陵路88號2幢3樓311室 | | 公司網址： | http://www.venusmedtech.com/ | | 電郵： | i ...

Investment Rating - The industry investment rating is "Positive" [6] Core Viewpoints - The report emphasizes the acceleration of domestic substitution due to centralized procurement, highlighting the importance of volume, price, and localization rates [11][15] - The IVD (In Vitro Diagnostics) market is experiencing rapid growth, with a market size of approximately 604 billion yuan in 2018, reflecting a year-on-year growth of 18.43% [30] - The report identifies significant opportunities in segments with low penetration rates and high growth potential, such as orthopedics, chemical luminescence, peripheral vascular intervention, electrophysiology, and TAVR [15] Summary by Sections Centralized Procurement - Centralized procurement has not affected manufacturers' ex-factory prices but has compressed intermediary channel profits, ensuring profit margins for production companies [11] - Various sub-sectors have low localization rates, allowing for competitive pricing to accelerate import substitution [11] IVD Market - The IVD market is segmented into biochemical diagnostics, immunodiagnostics, molecular diagnostics, microbiological diagnostics, and blood diagnostics, with the three main areas holding 46% of the global market share [30][31] - The market is characterized by a shift towards closed systems, which enhance accuracy and ease of use compared to open systems [33][34] Medical Devices and Equipment - The medical device sector is cyclical, with procurement activity peaking in December 2024, driven by demand recovery and policy implementation [24] - The report tracks hospital procurement data, indicating a seasonal pattern with the first half of the year typically being a low season for procurement [24] Medical Consumables - High-value consumables are seeing increased localization due to ongoing R&D investments and centralized procurement policies, while low-value consumables have a lower barrier to entry and higher domestic production rates [37][49] Electrophysiology and Gastroenterology - Electrophysiology devices and consumables are closely linked, with procedures conducted in catheterization labs [41] - Gastroenterology consumables are categorized based on their clinical applications, with a focus on devices used in endoscopic procedures [45][48]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州啓明醫療器械股份有限公司 (「本公司」) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份類別 ...

Core Viewpoint - The company reported a significant decline in revenue for the first half of 2025, primarily due to a decrease in product pricing driven by market competition and a shift in sales strategy [1] Revenue Performance - The company's revenue for the six months ending June 30, 2025, was RMB 187.1 million, representing an 18.9% year-on-year decrease [1] - The decline in revenue is attributed to two main factors: intense market competition leading to a strategic pricing adjustment, and a transition from a direct sales model to a platform sales model [1] Profitability - The loss attributable to equity holders of the parent company was RMB 135 million, compared to a loss of RMB 206 million in the same period last year [1]

Group 1 - The core viewpoint of the article is that Qiming Medical-B (02500) reported a decline in revenue and a reduction in shareholder losses for the six months ending June 30, 2025 [1] Group 2 - The company's revenue for the period was RMB 187 million, representing a year-on-year decrease of 18.9% [1] - The loss attributable to shareholders was RMB 135 million, which is a year-on-year narrowing of 34.7% [1] - The loss per share was RMB 0.31 [1]

Core Viewpoint - The company reported a decline in revenue and a reduced loss for the first half of the fiscal year ending June 30, 2025, indicating ongoing challenges but some improvement in financial performance [1] Financial Performance - The company's revenue for the six months was RMB 187 million, representing a year-on-year decrease of 18.9% [1] - The loss attributable to shareholders was RMB 135 million, which is a year-on-year reduction of 34.7% [1] - The loss per share was RMB 0.31 [1]

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 187,137, a decrease of 18.9% compared to RMB 230,720 for the same period in 2024[3]. - Gross profit for the same period was RMB 137,988, down 24.1% from RMB 181,760 in 2024[3]. - The company reported a pre-tax loss of RMB 138,564, which is a 35.1% improvement from a loss of RMB 213,581 in the previous year[3]. - Net loss for the period was RMB 134,772, a reduction of 35.5% compared to RMB 208,825 in 2024[3]. - Non-IFRS EBITDA loss was RMB 82,024, representing a 43.5% improvement from a loss of RMB 145,286 in the prior year[3]. - Non-IFRS commercial profit was RMB 30,363, down 11.0% from RMB 34,131 in 2024, with a commercial profit margin of 16.2%, up 1.4 percentage points year-on-year[3]. - The company's net loss attributable to ordinary shareholders was RMB 134,772,000 for the six months ended June 30, 2025, compared to RMB 206,487,000 for the same period in 2024[26]. - The non-IFRS EBITDA for the six months ended June 30, 2025, was RMB (82,024) thousand, an improvement from RMB (145,286) thousand in the same period of 2024[83]. - The non-IFRS commercial profit for the six months ended June 30, 2025, was RMB 30.4 million, with a commercial profit margin of 16.2%, up from 14.8% in the previous year[83][85]. Assets and Liabilities - Total non-current assets as of June 30, 2025, were RMB 2,387,393, a decrease from RMB 2,447,290 at the end of 2024[8]. - Current assets totaled RMB 732,622, down from RMB 802,480 at the end of 2024[9]. - Total liabilities amounted to RMB 1,053,748, with current liabilities at RMB 403,322 and non-current liabilities at RMB 650,426[9]. - The company's net assets were RMB 2,066,267, down from RMB 2,211,099 at the end of 2024[9]. - Trade receivables as of June 30, 2025, totaled RMB 137,529,000, down from RMB 198,567,000 as of December 31, 2024, with a significant decrease in receivables aged within 6 months[28]. - Total borrowings as of June 30, 2025, amounted to RMB 419.6 million, an increase from RMB 283.0 million as of December 31, 2024[89]. - The capital debt ratio increased to 23.9% as of June 30, 2025, compared to 16.7% as of December 31, 2024[89]. - The net current assets decreased to RMB 329.3 million as of June 30, 2025, down 25.3% from RMB 440.7 million as of December 31, 2024[90]. Market Performance - Revenue from the Chinese market was RMB 146,419,000, down 27% from RMB 200,620,000 in the previous year, while revenue from other countries/regions increased to RMB 40,718,000 from RMB 30,100,000[15]. - The VenusA series products generated RMB 138.5 million in revenue, representing 74.0% of total revenue for the first half of 2025, down from 82.9% in the same period of 2024[68]. - In the first half of 2025, the company's overseas revenue reached RMB 40.7 million, a year-on-year increase of 35.3%, accounting for 21.8% of total revenue[65]. - The company is expanding its market reach in Southeast Asia, targeting a 25% increase in market share by the end of 2024[119]. Research and Development - The company has established a product pipeline consisting of ten innovative devices, focusing on heart valve diseases, including four commercialized TAVR products and one TPVR product[41]. - R&D expenses for the six months ended June 30, 2025, and June 30, 2024, were RMB 120.9 million and RMB 180.8 million, representing 64.6% and 78.4% of the company's revenue, respectively[58]. - The company is focused on innovative medical devices for structural heart disease intervention, aiming to advance technology in China to meet patient needs[106]. - The company is committed to increasing R&D investment to maintain its leading position in the heart valve intervention field[56]. - The company has a clear and executable internationalization path supported by a leading R&D pipeline and a mature global commercialization system[108]. Operational Efficiency - Selling and distribution expenses decreased by 23.3% to RMB 100.5 million in the first half of 2025, with the selling expense ratio declining from 56.8% to 53.7%[72]. - Administrative expenses decreased by 28.5% to RMB 54.8 million in the first half of 2025, compared to RMB 76.6 million in the same period of 2024[75]. - Financing costs decreased by 26.5% to RMB 7.2 million in the first half of 2025, down from RMB 9.8 million in the same period of 2024, due to repayment of bank loans[78]. - The company continues to enhance operational efficiency through improved internal production systems and cost management strategies[40]. Corporate Governance - The company has complied with corporate governance codes applicable for the six months ending June 30, 2025[114]. - The audit committee has reviewed the interim financial results for the six months ending June 30, 2025, and found them to comply with relevant accounting standards[115]. - The board has recommended not to pay an interim dividend for the six months ending June 30, 2025[109]. Strategic Initiatives - The company plans to continue expanding its heart valve business in China and globally through organic growth and mergers and acquisitions to maximize shareholder value[100]. - The company is committed to finding strategic partners globally to explore overseas market opportunities through collaboration and joint ventures[107]. - The company aims to deepen its international market presence by integrating overseas resources and expanding into emerging markets while enhancing global sales capabilities[107]. - The company has established a global R&D network with centers in Hangzhou, Israel, and California, leveraging regional advantages for product innovation[57]. Product Development - The company is advancing the VenusP-Valve IDE (PROTEUS) pivotal clinical study in the U.S., which is expected to enroll 60 patients with severe pulmonary regurgitation[48]. - The VenusA-Valve, the first TAVR product approved in China, has a ten-year follow-up data showing a cardiac mortality rate of less than 20% and over 90% of patients experiencing no or minimal paravalvular regurgitation[45]. - VenusP-Valve, the first self-expanding TPVR product approved in Europe, received CE MDR certification in April 2022 and was approved for sale in China in July 2022, filling a clinical gap in the domestic market[46]. - The company is developing several TAVR products, including Venus-PowerX and Venus-Vitae valves[120].

Group 1 - The company, Qiming Medical-B (02500.HK), has announced a board meeting scheduled for August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] - The meeting will also consider the proposal for an interim dividend distribution, if applicable, along with other matters [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事會命 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 董事會召開日期 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）茲 通 告 謹 定 於 二 零 二 五 年 八 月 二 十 八 日（星 期 四）舉 行 董 事 會 會 議，以 審 議 及 批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績 及 其 發 佈，考 慮 建 議 派 發 中 期 股 息（如 有），以 及 處 理 其 他 事 項。 杭州啓明醫療器械股份有限公司 執行董事 林浩昇先生 杭州，二零二五年八月十八日 於本公告日期，執行董事為林浩昇先 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州啓明醫療器械股份有限公司 (「本公司」) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份類別 ...